Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: as the May 2025 FDA 510(k) clearance of Fujirebio Lumipulse G pTau217/beta-amyloid plasma ratio and the July 2025 Alzheimer's Association first clinical practice guideline endorsement convert blood-based AD testing from a research-tier laboratory-developed test into a cleared clinical diagnostic with professional society backing, so the market inflects from pre-commercial to early commercial phase and Fujirebio gains a two-year first-mover IVD advantage over Roche, Abbott, and ALZpath, and so the commercial trajectory concentrates around payer reimbursement resolution and anti-amyloid therapy prescription volume growth that creates mandatory pre-treatment diagnostic demand at the approximately 6.9 million Americans living with Alzheimer's disease.

The global blood-based biomarker for Alzheimer's disease diagnostics market size was USD 148.4 Million in 2025 and is expected to register a revenue CAGR of 22.8% during the forecast period. Market revenue growth is driven by factors such as the FDA 510(k) clearance of the Fujirebio Lumipulse G pTau217/beta-Amyloid 1-42 Plasma Ratio test in May 2025 as the first blood-based IVD to aid in diagnosing Alzheimer's disease, the Alzheimer's Association first clinical practice guideline issued in July 2025 incorporating blood-based biomarker testing in the AD diagnosis pathway, as well as the commercial expansion of anti-amyloid disease-modifying therapies that creates mandatory pre-treatment amyloid confirmation diagnostic demand at the approximately 6.9 million Americans living with Alzheimer's dementia. The first driving factor is the FDA 510(k) clearance of Fujirebio Lumipulse, which on May 16, 2025 became the first blood-based IVD device cleared by the FDA to aid in diagnosing Alzheimer's disease by detecting amyloid pathology in patients aged 55 and older exhibiting signs and symptoms of the disease, resolving the regulatory grey zone in which LDT blood-based AD tests had operated since Labcorp and Quest Diagnostics first offered them to neurologists and memory clinic physicians. The second driving factor is the Alzheimer's Association July 2025 clinical practice guideline, which for the first time incorporated recommendations on blood-based biomarker testing in the AD diagnosis pathway alongside amyloid PET and cerebrospinal fluid testing, establishing the professional society clinical guideline endorsement that neurologists and memory clinic physicians require before routinely ordering a new diagnostic test category. The third driving factor is the Labcorp nationwide launch of the FDA-cleared Lumipulse plasma pTau217/Abeta1-42 test on August 18, 2025, which created the first population-scale commercial distribution channel for an FDA-cleared blood-based Alzheimer's IVD through approximately 2,000 Labcorp patient service centres and physician ordering portals across the United States. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way the FDA prescribing label requirement for amyloid pathology confirmation before initiating anti-amyloid disease-modifying therapy with Leqembi (lecanemab, Eisai and Biogen) or Kisunla (donanemab, Eli Lilly) creates a mandatory diagnostic gateway that converts each new anti-amyloid therapy prescription into a required blood-based biomarker test order or amyloid PET scan at a cost differential of USD 400 to USD 1,200 versus USD 4,000 to USD 6,000 that systematically favours the blood-based test in the pre-treatment diagnostic pathway. Once a neurologist or memory clinic physician has initiated a patient on the anti-amyloid therapy pre-treatment evaluation pathway, each subsequent patient presenting for Leqembi or Kisunla consideration requires the same amyloid confirmation diagnostic step, so the diagnostic demand compounds with each incremental anti-amyloid therapy prescriber who adopts the DMT prescribing pathway, without requiring additional commercial investment by Fujirebio or Labcorp to capture that demand. As a result, blood-based AD diagnostic demand concentrates around Fujirebio Lumipulse as the only FDA-cleared IVD test in the category, and the forecast tilts toward the FDA-cleared IVD channel rather than toward the LDT channel as payer reimbursement policies progressively distinguish between cleared IVD tests and uncleared LDTs in coverage determinations. For instance, in December 2024, Fujirebio signed a collaboration agreement with Eisai to jointly study and promote blood-based biomarkers for neurodegenerative diseases, positioning the Lumipulse blood-based platform alongside Eisai's commercial neurologist relationship infrastructure and Leqembi prescribing network, one of the first diagnostic-therapy commercial alignment partnerships in the blood-based AD diagnostic market that links the Fujirebio test directly to the anti-amyloid therapy patient identification and monitoring workflow. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the FDA 510(k) clearance of the Fujirebio Lumipulse G pTau217/beta-Amyloid 1-42 Plasma Ratio test, which on May 16, 2025 became the first blood-based in vitro diagnostic device cleared by the FDA to aid in diagnosing Alzheimer's disease, having received FDA Breakthrough Device Designation that expedited the review process and enabling use in adults aged 55 and older exhibiting signs and symptoms of the disease. This clearance works only if the diagnostic platform is accessible to the neurology and memory clinic physicians who order the test, and as Labcorp's nationwide launch on August 18, 2025 distributed the FDA-cleared Lumipulse test through approximately 2,000 patient service centres and physician ordering portals, the commercial infrastructure for at-scale ordering was established within three months of FDA clearance, compressing the regulatory-to-commercial conversion timeline to the shortest in blood-based diagnostic history for a novel neurological biomarker category. The pre-clearance Labcorp and Quest Diagnostics LDT blood-based AD biomarker programmes, which had offered plasma amyloid beta 42/40 ratio, pTau181, NfL, and GFAP tests to neurologists for several years preceding the Fujirebio FDA clearance, established the clinical ordering workflow and physician familiarity that allows the FDA-cleared IVD test to enter a partially prepared clinical ordering environment rather than a zero-awareness market. The recent regulatory calendar shows the pace. The Fujirebio Lumipulse 510(k) clearance in May 2025 preceded the Alzheimer's Association clinical practice guideline by six weeks, creating a paired regulatory clearance and clinical guideline package that resolves both the regulatory and the professional society endorsement barriers to clinical adoption simultaneously. The effect on the market is the inflection of the blood-based AD diagnostic market from a pre-commercial LDT research utility phase into a cleared IVD commercial diagnostic category with population-scale Labcorp distribution infrastructure, professional society guideline endorsement, and a growing anti-amyloid therapy prescribing volume that creates mandatory pre-treatment diagnostic demand. These are some of the key factors driving revenue growth of the market.

The second driver is the Alzheimer's Association first clinical practice guideline for Alzheimer's diagnosis and care, issued in July 2025 at the Alzheimer's Association International Conference in Toronto, which for the first time positioned plasma pTau217/Abeta1-42 testing alongside amyloid PET and cerebrospinal fluid testing in the clinical AD diagnostic pathway and established the professional society endorsement that neurologists and memory clinic physicians reference when adopting a new diagnostic test category into clinical practice. The Alzheimer's Association 2024 Facts and Figures report estimated that 6.9 million Americans aged 65 and older were living with Alzheimer's dementia, with approximately 200,000 Americans under age 65 having younger-onset Alzheimer's, and that the number could grow to 13.8 million by 2060, establishing the epidemiological scale of the diagnostic need that blood-based biomarker testing is positioned to address. The total US Alzheimer's care costs of USD 360 billion in 2024, a USD 15 billion increase from 2023, establish the health economic context for earlier and more accessible diagnostic pathways that can accelerate treatment initiation for patients who would benefit from anti-amyloid disease-modifying therapy. The Fujirebio-Eisai collaboration agreement signed in December 2024 positions the Lumipulse blood-based biomarker platform alongside Eisai and Biogen's Leqembi commercial strategy, linking blood-based AD diagnostic adoption to anti-amyloid therapy prescribing infrastructure at US neurology and memory clinic practices that are initiating Leqembi treatment. The effect on the market is a progressive normalisation of blood-based AD biomarker testing as a standard component of the neurological evaluation for patients presenting with cognitive concerns, converting what had been a research-oriented diagnostic modality into a routine clinical ordering category supported by the guideline endorsement and FDA clearance infrastructure required for institutional procurement and payer coverage consideration. These are some of the key factors driving revenue growth of the market.

The Fujirebio FDA 510(k) clearance in May 2025 and the Alzheimer's Association clinical practice guideline in July 2025, issued six weeks later, form the first paired regulatory clearance and professional society guideline package for a blood-based AD diagnostic, resolving simultaneously the two barriers that had confined blood-based AD testing to the LDT regulatory grey zone. Labcorp's nationwide launch on August 18, 2025 through approximately 2,000 patient service centres compressed the regulatory-to-commercial distribution timeline to under 100 days from FDA clearance.

The third driver is the mandatory amyloid pathology confirmation requirement in the FDA prescribing labels for Leqembi (lecanemab) and Kisunla (donanemab), which requires that physicians confirm amyloid pathology before prescribing either anti-amyloid disease-modifying therapy, creating a direct link between anti-amyloid therapy prescription volume and blood-based AD diagnostic test demand that does not depend on physician adoption behaviour or voluntary guideline compliance. The blood-based testing cost of approximately USD 400 to USD 1,200 per test in the LDT channel compared with USD 4,000 to USD 6,000 for amyloid PET scans creates a USD 3,000 to USD 5,000 per-patient cost advantage for blood-based testing as the first-line amyloid screening tool, which systematically favours blood-based AD testing within payer management of the anti-amyloid therapy reimbursement pathway. In December 2024, Fujirebio signed a collaboration agreement with Eisai to jointly study and promote blood-based biomarkers for neurodegenerative diseases, leveraging Eisai's neurologist relationship infrastructure to position Lumipulse blood-based biomarker testing within the Leqembi pre-treatment evaluation workflow at US memory clinic and neurology practice accounts that are initiating Leqembi in eligible patients. The effect on the market is that anti-amyloid therapy prescription volume growth creates a volume floor for blood-based AD diagnostic demand that is independent of voluntary physician adoption behaviour and instead directly proportional to the number of patients entering anti-amyloid therapy evaluation pathways, providing a structural demand driver that sustains the 22.8% CAGR forecast even if voluntary physician blood-based AD test ordering outside the anti-amyloid therapy pathway grows more slowly than projected. These are some of the key factors driving revenue growth of the market.

However, the blood-based biomarker for Alzheimer's disease diagnostics market faces adoption constraints from the absence of Medicare Local Coverage Determinations, the primary care physician familiarity gap, and confirmatory testing requirements that collectively limit the FDA clearance from translating into immediate population-scale ordering volume. Because Medicare coverage for the Fujirebio Lumipulse plasma test under the CMS Local Coverage Determination framework had not been concluded as of Q2 2026, patients and ordering physicians face out-of-pocket costs or uncertain reimbursement at a test cost of USD 400 to USD 1,200, creating a total cost access barrier that prevents routine ordering beyond the commercially insured neurology patient population able to absorb out-of-pocket diagnostic costs while awaiting CMS policy development. Primary care physician test familiarity is a second constraint, since the Alzheimer's Association 2024 Facts and Figures documented that 55% of primary care physicians report insufficient dementia specialist availability in their communities to support timely referral, limiting ordering volume to the neurologist and memory clinic channel rather than expanding to the primary care volume that would generate population-scale adoption, and specialist access bottlenecks mean that most patients with cognitive concerns are not reaching neurologists who are positioned to order blood-based AD tests in a timely clinical evaluation pathway. Confirmatory testing requirement is the third constraint, since Fujirebio Lumipulse indeterminate results require downstream confirmatory testing with amyloid PET or CSF analysis for a proportion of tested patients, maintaining cost and access burden for a fraction of tested patients and limiting the blood-based test from fully replacing rather than complementing the existing high-cost diagnostic modalities until clinical performance data in broader real-world populations demonstrate sufficient sensitivity and specificity to reduce the indeterminate result rate across diverse patient demographics. These factors substantially limit blood-based biomarker for Alzheimer's disease diagnostics market growth over the forecast period.

Based on end-use, the global blood-based Alzheimer's diagnostics market is segmented into neurology and memory clinics, hospital laboratories, independent reference laboratories, and research and clinical trial sites. Neurology and memory clinics hold the largest institutional demand share, because the prescribing decision for anti-amyloid disease-modifying therapies originates with neurologists and geriatric psychiatrists who order the pre-treatment amyloid confirmation diagnostic, and the FDA prescribing information for Leqembi and Kisunla requires confirmation of amyloid pathology before treatment initiation, making blood-based biomarker testing a mandatory component of the neurologist-initiated anti-amyloid therapy evaluation pathway. Research and clinical trial sites are expected to register a rapid revenue growth rate as blood-based biomarkers replace CSF lumbar punctures and amyloid PET scans as the preferred screening and monitoring tool in AD clinical trials, with Quanterix Simoa, ALZpath, and RUO platform tests serving the research market and reducing screen failure rates and participant burden in Alzheimer's disease clinical programmes.

Based on application, the global blood-based Alzheimer's diagnostics market is segmented into clinical diagnosis and patient screening for disease-modifying therapy eligibility. Clinical diagnosis accounts for the largest current revenue share through the established LDT market at Labcorp and Quest Diagnostics. The patient screening for DMT eligibility application is expected to register a rapid revenue growth rate over the forecast period, driven by the FDA prescribing label requirement for amyloid confirmation before Leqembi and Kisunla prescribing, and the commercial expansion of anti-amyloid therapies that is creating a growing population of patients requiring pre-treatment diagnostic testing, with blood-based testing at USD 400 to USD 1,200 per test positioned as the primary first-line amyloid screening tool in the DMT eligibility pathway given its significant cost advantage versus USD 4,000 to USD 6,000 amyloid PET, which is why Fujirebio's Labcorp distribution partnership is strategically aligned with anti-amyloid therapy prescription growth at US neurology accounts.

Based on regional analysis, the blood-based Alzheimer's biomarker diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the FDA 510(k) clearance of Fujirebio Lumipulse in May 2025 created the first commercially cleared blood-based Alzheimer's IVD available in any national market, combined with the Labcorp nationwide launch in August 2025 providing immediate distribution scale through approximately 2,000 patient service centres across the United States. The Alzheimer's Association documented 6.9 million Americans aged 65 and older with Alzheimer's dementia in 2024, representing the world's largest single-country Alzheimer's patient population in an advanced healthcare system with both anti-amyloid therapy availability and the Labcorp and Quest Diagnostics clinical laboratory infrastructure required to support a national blood-based biomarker programme at scale. The concentration of Alzheimer's disease clinical trial activity and anti-amyloid therapy prescribing at US academic neurology centres also means blood-based AD biomarker test ordering volume is highest at US institutions, ahead of European and Asia Pacific markets where anti-amyloid therapy availability is still expanding.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Fujirebio's Lumipulse G platform has CE marking in Europe and has been used in clinical research and early diagnostic settings at European memory clinics ahead of the US 510(k) clearance. Roche Diagnostics is conducting data collection to support blood-based Alzheimer's test regulatory submissions in European markets, with Roche's cobas analyzer platform already installed in the majority of European hospital clinical chemistry laboratories representing a potential distribution advantage over Fujirebio's standalone Lumipulse analyzer in European hospital laboratory settings. The 2026 to 2027 Iran-US sanctions and Strait of Hormuz logistics disruptions affecting specialty immunoassay reagent supply routes create component cost pressure for Fujirebio's European supply chain for Lumipulse platform reagent kits manufactured at Tokyo-based production facilities and distributed through European logistics networks, maintaining elevated reagent import cost premiums through 2026 that compress distributor margins for European Lumipulse commercial partners. The result is steady rather than rapid European growth, shaped more by IVDR regulatory certification timelines and CMS-equivalent national health system reimbursement approval processes than by underlying clinical demand.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, and Australia represent the three largest national markets within the region. Japan represents Fujirebio's home market and the Lumipulse platform has the longest commercial history in Japanese laboratory settings, with the Fujirebio-Eisai collaboration signed in December 2024 aligning blood-based biomarker adoption with Eisai's commercial strategy for Leqembi in Japan and leaving more room for growth than in North America where the FDA-cleared IVD market is already being established, given that Japanese anti-amyloid therapy prescribing and blood-based AD biomarker clinical adoption are at earlier commercial stages.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region. Alzheimer's disease prevalence in Latin America is rising with an ageing population, with the Alzheimer's Association projecting increasing global Alzheimer's prevalence as the population aged 65 and older grows, concentrating AD diagnostic demand growth in Brazilian and Mexican private hospital neurology programmes that serve the commercially insured patient population able to access blood-based AD biomarker testing at current pricing. The indirect effects of Iran-US sanctions on international freight costs along South American trade routes have maintained elevated import costs for blood-based Alzheimer's diagnostic test kits and Lumipulse reagents entering Brazilian and Mexican laboratory distribution networks through 2026, suppressing adoption beyond the main private-sector hospital centres in São Paulo, Mexico City, and Buenos Aires where procurement budgets can absorb the premium.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the GCC. Cleveland Clinic Abu Dhabi and King Faisal Specialist Hospital in Riyadh operate the highest-volume neurology programmes in the GCC with memory clinic capabilities managing Alzheimer's disease and other dementia patients, representing the early-adopter accounts for blood-based AD biomarker testing in the region. South Africa is the most established market on the continent for advanced neurological diagnostics, with private hospital neurology programmes at Mediclinic and Netcare hospital groups representing the primary commercial channel for blood-based AD biomarker test access, while Gulf state public hospital systems are still building the memory clinic infrastructure and anti-amyloid therapy access pathways that generate systematic blood-based AD diagnostic ordering volume.